27 Jul 2017

UCB with a strong first half year 2017 – giving rise to the financial outlook for 2017

Read More
25 Jul 2017

UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis

Read More
24 Jul 2017

UCB’s anti-epileptic drug VIMPAT® (lacosamide) receives EU CHMP positive opinion for both monotherapy and adjunctive therapy in children aged 4 years and older with epilepsy

Read More
21 Jul 2017

Bimekizumab Demonstrates Skin Clearance in Phase 2b Psoriasis Study with first monoclonal antibody neutralizing both IL-17A and IL-17F 

Read More
17 Jul 2017

UCB and Amgen Provide Update on Regulatory Status of EVENITY™ (romosozumab) in the U.S.

Read More
14 Jun 2017

New study illustrates large treatment gap in post-fracture care management

Read More
13 Jun 2017

UCB announces four-year imaging results demonstrating low disease progression and long-term efficacy of CIMZIA® (certolizumab pegol) in patients with axial spondyloarthritis (axSpA)

Read More
13 Jun 2017

Results from CRIB study on CIMZIA® (certolizumab pegol) demonstrate minimal to no placental transfer of drug from mother to infant during third trimester of pregnancy

Read More
13 Jun 2017

New UCB data demonstrates scientific innovation for immunology patients with high unmet needs at the Annual European Congress of Rheumatology (EULAR) 2017

Read More
8 Jun 2017

Transparency notification BlackRock, Inc.

Read More
Subscribe to